Non-alcoholic Steatohepatitis Clinical Trials Market Size Worth $4.2 Billion By 2030: Grand View Research, Inc.

SAN FRANCISCO, Feb. 1, 2022 /PRNewswire/ -- The global non-alcoholic steatohepatitis clinical trials market size is expected to reach USD 4.2 billion by 2030, registering a CAGR of 6.5% over the forecast period, according to a new report by Grand View Research, Inc. Rising healthcare expenditure, cases of obesity, and prevalence of non-alcoholic steatohepatitis (NASH) are the factors driving the growth of this market. Due to the COVID-19 pandemic, enrollment in new drug clinical trials for NASH patients was halted, but people shifted to alternate means of data collecting methods, like virtual visits. Non-alcoholic Steatohepatitis is a fatty liver disease that causes scarring and damage to the liver.

Key Insights & Findings from the report:

• The phase III segment dominated the global market in 2021. These trials cost more than USD 100 million
• The interventional study design segment held the largest revenue share in 2021. There were 84 ongoing interventional studies with patients enrolled in December 2019 to evaluate the therapeutic efficacy of treatments for NASH
• North America dominated the global market in 2021 due to the increased number of NASH patients in the region
• According to the U.S. National Library of Medicine 2018, instances of NASH in the U.S. are expected to increase 63% from 16.52 million to 27.00 million cases by 2030
• Asia Pacific is projected to register the fastest CAGR over the forecast period owing to the increasing incidence of associated risk factors, such as obesity, type 2 diabetes (T2D), dyslipidemia, and other metabolic diseases with substantial diagnostic improvements using ultrasound and biomarkers

Read 100 page market research report, "Non-alcoholic Steatohepatitis Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, II, III, IV), By Study Design (Interventional, Expanded Access), By Region (APAC, Europe), And Segment Forecasts, 2022 - 2030", published by Grand View Research.

NASH has no FDA-approved treatment and can proceed to the point where patients need a liver transplant in extreme situations. NASH, like diabetes, is linked to obesity and a high-sugar diet. Some pharmaceutical companies are testing whether diabetes drugs could help NASH patients. However, the COVID-19 pandemic has thrown a wrench into every element of NASH clinical trials, from patient recruiting to IP administration and safety monitoring to data integrity. As clinical research monitors are not allowed to travel, remote electronic monitoring is a viable alternative to traditional on-site monitoring. Monitors could receive information from research locations by paper mail, e-mail (allowing direct access to electronic medical records), or remote monitoring systems.

In December, the FDA issued guidance urging the pharmaceutical sector to develop and confirm improved biomarkers for the diagnosis and progression of NASH. In many aspects, getting past the biopsy barrier is significant compared to a lack of general awareness of NASH, that's why it is critical for pharmaceutical companies to invest in innovations (such as a variety of imaging techniques) to alleviate this patient burden, and then persuade the FDA with positive data to accept those advancements as appropriate end-point markers for clinical trials.

Market Segmentation:

Grand View Research has segmented the global non-alcoholic steatohepatitis clinical trials market based on phase, study design, and region:

• NASH Clinical Trials Phase Outlook (Revenue, USD Million, 2018 - 2030)
• Phase I
• Phase II
• Phase III
• Phase IV
• NASH Clinical Trials Study Design Outlook (Revenue, USD Million, 2018 - 2030)
• Interventional
• Observational
• Expanded Access
• NASH Clinical Trials Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Italy
• Spain
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• List of Key Players of Non-alcoholic Steatohepatitis Clinical Trials Market
• Pfizer Inc.
• Novartis AG
• Icon Plc
• LabCorp
• Allergan Plc
• Cadila Healthcare Ltd.
• Shire Plc (Takeda Pharmaceuticals)
• Eli Lilly
• Novo Nordisk
• Gilead Sciences Inc.
• Glaxosmith Kline
• Arrowhead Pharmaceuticals

Check out more studies related to clinical trials, published by Grand View Research:

• Clinical Trials Management System Market – The global Clinical Trials Management System (CTMS) market size was valued at USD 592.07 million in 2016. It is anticipated to expand at a CAGR of 12.1% over the forecast period. Rapid growth of healthcare IT and increasing R&D expenditure by life science and clinical research organization and increasing adoption of CTMS solutions is anticipated to drive the growth of the market.
• Neurology Clinical Trials Market – The global neurology clinical trials market size was estimated at USD 4.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 5.5% from 2021 to 2028. This is largely attributed to increasing neurological diseases, such as dementia, stroke, and peripheral neuropathy, and growing R&D investments towards neurological research.
• Omics-Based Clinical Trials Market – The global omics-based clinical trials market size was valued at USD 26.2 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 7.4% from 2022 to 2030. There was unprecedented growth in 2020 due to the COVID-19 pandemic.

Browse through Grand View Research's coverage of the Global Medical Devices Industry.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg